½ÃÀ庸°í¼­
»óǰÄÚµå
1726384

¼¼°èÀÇ ¸¶ÀÌÅ©·Î¾î·¹ÀÌ ½ÃÀå : ½ÃÀå ±Ô¸ð, Á¡À¯À² ¹× µ¿Ç⠺м® - Á¦Ç° ¹× ¼­ºñ½ºº°, À¯Çüº°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2025-2030³â)

Microarray Market Size, Share & Trends Analysis Report By Product And Services (Instruments, Consumables), By Type, By Application (Drug Discovery, Disease Diagnostics), By End-use, By Region, And Segment Forecasts, 2025 - 2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Grand View Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 145 Pages | ¹è¼Û¾È³» : 2-10ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¸¶ÀÌÅ©·Î¾î·¹ÀÌ ½ÃÀåÀÇ ¼ºÀå ¹× µ¿Çâ :

Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼­¿¡ µû¸£¸é ¼¼°èÀÇ ¸¶ÀÌÅ©·Î¾î·¹ÀÌ ½ÃÀå ±Ô¸ð´Â 2030³â±îÁö 84¾ï 6,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ Àü¸ÁÀ̸ç, 2025-2030³â CAGR 5.48%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

½ÃÀå ¼ºÀå ÃËÁø¿äÀÎÀ¸·Î´Â ¼¼°èÀÇ ¾Ï ȯÀÚ Áõ°¡, ½ÃÄö½Ì, À¯Àüü ¸ÅÇÎ, ¸ÂÃãÇü ÀÇ·á µî¿¡ À־ ¸¶ÀÌÅ©·Î¾î·¹ÀÌÀÇ Æø³ÐÀº ¿ëµµ¸¦ µé ¼ö ÀÖ½À´Ï´Ù. ¶Ç, ¼¼°è ¿¬±¸°³¹ß ÅõÀÚ Áõ°¡ ¶ÇÇÑ ÇコÄɾîÀÇ Áøº¸ ¹× Çâ»óÀ» À§ÇÑ ¿¬±¸ ¸ñÀûÀ¸·ÎÀÇ ¸¶ÀÌÅ©·Î¾î·¹ÀÌ »ç¿ë Áõ°¡·Î À̾îÁö±â ¶§¹®¿¡, ¼ºÀåÀ» °¡¼ÓÇÏ´Â ¿­¼è°¡ µË´Ï´Ù.

¸¶ÀÌÅ©·Î¾î·¹ÀÌ´Â ¿¬±¸ ¿ëµµ, â¾à, Áúº´Áø´Ü, À¯Àüü ¹× ÇÁ·ÎÅ×¿È ¿¬±¸, ½Ä¹° ¹× ½Äǰ¿¬±¸, ³ó¾÷¿¬±¸ µî Æø³ÐÀº ¿ëµµ°¡ ÀÖ½À´Ï´Ù. ¹Ì±¹½Å°æÇÐȸ°¡ ¹ßÇ¥ÇÑ º¸°í¼­¿¡ µû¸£¸é ¿°»öü ¸¶ÀÌÅ©·Î¾î·¹ÀÌ ÇØ¼®Àº ÁöÀûÀå¾Ö ¹× µð½º¿À¹Í Áø´Ü¿¡ »ç¿ëÇÒ ¼ö ÀÖÀ¸¸ç, ÀÌ °Ë»ç´Â ù ¹øÂ° ¼±ÅÃÀÇ Áø´Ü°Ë»ç·Îµµ ±ÇÀåµÇ°í ÀÖ½À´Ï´Ù. ÃÖ±ÙÀÇ ÇÁ·ÎÅ׿À¹Í½º ¹× À¯ÀüüÇÐÀÇ Áøº¸´Â Àΰ£ °Ô³ðÀÇ ¿°±â¼­¿­ °áÁ¤°ú ¸Â¹°·Á ½ºÅ©¸®´× °¡´ÉÇÑ Ã¢¾à Ç¥ÀûÀ» Áõ°¡½Ã۰í ÀÖ½À´Ï´Ù. PNAS(Proceedings of the National Academy of Sciences of the United States of America)¿¡ °ÔÀçµÈ º¸°í¿¡ µû¸£¸é, ÇÏÀÌ Ã³¸®·® µ¶¼ºÇÐÀû ºÐ¼®¿ëÀ¸·Î ¼ÒÇü 3Â÷¿ø ¼¼Æ÷¹è¾ç ¸¶ÀÌÅ©·Î¾î·¹À̰¡ °³¹ßµÇ¾ú½À´Ï´Ù.

ÁÖ¿ä ±â¾÷ÀÌ ´Ù¾çÇÑ À¯ÇüÀÇ ¾î·¹ÀÌ Ç÷§ÆûÀ» µµÀÔÇÏ´Â °Íµµ ½ÃÀåÀÇ ÀáÀç·ÂÀ» ³ôÀÏ °ÍÀ¸·Î ¿¹»óµÇ´Â ¿äÀÎÀÔ´Ï´Ù. ¿¹¸¦ µé¾î »ý¹°ÇÐÀû Á¦Ç°À» ´Ù·ç´Â ±â¾÷ÀÎ R&D ½Ã½ºÅÛÁî´Â ÇÁ·ÎÅ×¿È ÇÁ·ÎÆÄÀÏ·¯ Ç×ü ¾î·¹À̸¦ Á¦°øÇϰí ÀÖÀ¸¸ç, ÀÌ´Â ÇϳªÀÇ »ùÇ÷Π119°¡Áö ÀÌ»óÀÇ ´Ü¹éÁúÀ» ÃøÁ¤Çϱâ À§ÇÑ ´Ü¹éÁú ¸¶ÀÌÅ©·Î ¾î·¹ÀÌÀÔ´Ï´Ù. ÀÌ Á¦Ç°À» »ç¿ëÇÔÀ¸·Î½á ·¦ÀÇ ±â¼úÀڴ Ưº°ÇÑ ÀåÄ¡¸¦ ÇÊ¿ä·Î ÇÏÁö ¾ÊÀ¸¸ç, ³ª¾Æ°¡ ¿þ½ºÅÏ ºí·Ô ½ÇÇèÀÇ Çʿ伺µµ ¾ø¾îÁý´Ï´Ù.

ÃÖ±Ù ¼ö³â°£ ´ë±Ô¸ð ½ÃÀå ±â¾÷Àº ±âÁ¸ Á¦Ç° Æ÷Æ®Æú¸®¿À¿Í Áö¸®Àû Á¸À縦 È®´ëÇϱâ À§ÇØ Áß¼Ò±â¾÷°ú Á¦ÈÞÇØ ¿Ô½À´Ï´Ù. ¿¹¸¦ µé¾î, 2018³â¿¡ ¸ÓÅ©´Â HistoCyte Laboratories Ltd.¿Í °è¾àÀ» ü°áÇÏ°í ¹Ì±¹ ¹× ±âŸ Áö¿ª¿¡¼­ ¼¼Æ÷ ¸¶ÀÌÅ©·Î¾î·¹À̸¦ ÆÇ¸ÅÇÔÀ¸·Î½á ¿¬±¸Àڵ鿡°Ô ºñ¿ë È¿À²ÀûÀÌ°í °£´ÜÇÑ ¿É¼ÇÀ» Á¦°øÇÕ´Ï´Ù.

¾Æ½Ã¾ÆÅÂÆò¾çÀº ¼±µµÀûÀÎ ±â¾÷ÀÇ ¸¶ÀÌÅ©·Î¾î·¹ÀÌ ½ÂÀÎ Áõ°¡·Î ÀÎÇØ ¿¹Ãø ±â°£ µ¿¾È À¯¸®ÇÑ ¼ºÀåÀÌ ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¸é, 2015³â, Agilent Technologies Inc.´Â, ÀÌ È¸»çÀÇ SureScan Dx ¸¶ÀÌÅ©·Î¾î·¹ÀÌ ½ºÄ³³Ê¿¡ ´ëÇØ Áß±¹ FDAÀÇ Àΰ¡¸¦ ÃëµæÇß½À´Ï´Ù. Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« Áö¿ªµµ Áúº´ Áø´ÜÀ» °³¼±Çϱâ À§ÇÑ ½ÅÁ¦Ç° Ãâ½Ã·Î Àý´ëÀûÀÎ ºñÁî´Ï½º ±âȸ¸¦ ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î 2017³â Thermo Fisher Scientific, Inc.´Â Axiom Africa ¾î·¹À̸¦ Ãâ½ÃÇß½À´Ï´Ù. ÀÌ ¹è¿­Àº ¾ÆÇÁ¸®Ä« Áý´Ü»Ó¸¸ ¾Æ´Ï¶ó À¯·´°ú ¾Æ½Ã¾Æ Áý´ÜÀÇ °Ô³ð ÀüüÀÇ º¯À̸¦ ÆÄ¾ÇÇÕ´Ï´Ù.

¸¶ÀÌÅ©·Î¾î·¹ÀÌ ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®

  • 2024³â ½ÃÀå Á¡À¯À²Àº ¼Ò¸ðǰÀÌ 49.73%·Î ÃÖ´ë¿´½À´Ï´Ù. ºÐÀÚÁø´Ü ¹× ¿¬±¸ ¿ëµµÀÇ ÀÚµ¿È­, °íÁ¤¹ÐÈ­, È®À强¿¡ ´ëÇÑ ¿ä±¸°¡ Áõ°¡ÇÔ¿¡ µû¶ó ¿¹Ãø ±â°£ µ¿¾È ÀåÄ¡°¡ °¡Àå ºü¸¥ ¼Óµµ·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
  • DNA ¸¶ÀÌÅ©·Î¾î·¹ÀÌ´Â 2024³â¿¡ ÃÖ´ëÀÇ ¼öÀÍ Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ´Ü¹éÁú ¸¶ÀÌÅ©·Î¾î·¹À̴ â¾à, ¸é¿ª ÇÁ·ÎÆÄÀϸµ, ¹ÙÀÌ¿À¸¶Ä¿ °ËÁõ¿¡¼­ÀÇ »ç¿ë Áõ°¡·Î ¿¹Ãø ±â°£ µ¿¾È °¡Àå ºü¸¥ ¼ºÀåÀÌ Àü¸ÁµÇ°í ÀÖ½À´Ï´Ù.
  • 2024³â ¸¶ÀÌÅ©·Î¾î·¹ÀÌ ½ÃÀåÀº À¯ÀüüÇÐ, ´Ü¹éÁúüÇÐ, ¹ÙÀÌ¿À¸ÞµðÄà Çõ½Å¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡¿¡ ÈûÀÔ¾î ¿¬±¸ ¿ëµµ°¡ Áö¹èÀûÀ̾ú½À´Ï´Ù. Áúº´ Áø´ÜÀº ¿¹Ãø ±â°£ µ¿¾È °¡Àå ºü¸¥ ¼Óµµ·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù.
  • 2024³â ½ÃÀå ¼öÀÍ Á¡À¯À²Àº ¿¬±¸±â°ü ¹× Çмú±â°üÀÌ ÃÖ´ë¿´½À´Ï´Ù. Áø´Ü ·¦ ºÎ¹®Àº ¿¹Ãø ±â°£ µ¿¾È °¡Àå ºü¸¥ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
  • ºÏ¹ÌÀÇ ¸¶ÀÌÅ©·Î¾î·¹ÀÌ ½ÃÀåÀº ¼¼°è »ê¾÷À» Áö¹èÇØ 2024³â¿¡´Â 48.27%ÀÇ Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ¸¶ÀÌÅ©·Î¾î·¹ÀÌ ½ÃÀåÀº, ¿¬±¸ °³¹ß Ȱµ¿¿¡ ´ëÇÑ ÅõÀÚÀÇ Áõ°¡·Î Å« ¼ºÀåÀÌ Àü¸ÁµÇ°í ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ºÐ¼® ¹æ¹ý ¹× ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ¸¶ÀÌÅ©·Î¾î·¹ÀÌ ½ÃÀå : º¯µ¿ ¿äÀÎ, °æÇâ ¹× ¹üÀ§

  • ½ÃÀå ¿¬°ü Àü¸Á
    • »óÀ§ ½ÃÀå Àü¸Á
    • °ü·Ã ¹× ºÎ¼ö ½ÃÀå Àü¸Á
  • ½ÃÀå ¿ªÇÐ
    • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ ºÐ¼®
    • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
  • ¸¶ÀÌÅ©·Î¾î·¹ÀÌ ½ÃÀå : ºÐ¼® Åø
    • ¾÷°è ºÐ¼® : Porter's Five Forces ºÐ¼®
    • PESTEL ºÐ¼®

Á¦4Àå ¸¶ÀÌÅ©·Î¾î·¹ÀÌ ½ÃÀå : Á¦Ç° ¹× ¼­ºñ½ºº° ÃßÁ¤ ¹× µ¿Ç⠺м®

  • ½ÃÀå Á¡À¯À² : Á¦Ç° ¹× ¼­ºñ½ºº°(2023³â, 2030³â)
  • ºÎ¹® ´ë½Ãº¸µå
  • ¼¼°èÀÇ ¸¶ÀÌÅ©·Î¾î·¹ÀÌ ½ÃÀå Àü¸Á : Á¦Ç° ¹× ¼­ºñ½ºº°
  • ½ÃÀå ±Ô¸ð ¿¹Ãø ¹× µ¿Ç⠺м®(2018-2030³â)
    • ¼Ò¸ðǰ
    • ÀåÄ¡
    • ¼ÒÇÁÆ®¿þ¾î ¹× ¼­ºñ½º

Á¦5Àå ¸¶ÀÌÅ©·Î¾î·¹ÀÌ ½ÃÀå : À¯Çüº° ÃßÁ¤ ¹× µ¿Ç⠺м®

  • ½ÃÀå Á¡À¯À² : À¯Çüº°(2023³â, 2030³â)
  • ºÎ¹® ´ë½Ãº¸µå
  • ¼¼°èÀÇ ¸¶ÀÌÅ©·Î¾î·¹ÀÌ ½ÃÀå Àü¸Á : À¯Çüº°
  • ½ÃÀå ±Ô¸ð ¿¹Ãø ¹× µ¿Ç⠺м®(2018-2030³â)
    • DNA ¸¶ÀÌÅ©·Î¾î·¹ÀÌ
    • ´Ü¹éÁú ¸¶ÀÌÅ©·Î¾î·¹ÀÌ
    • ±âŸ

Á¦6Àå ¸¶ÀÌÅ©·Î¾î·¹ÀÌ ½ÃÀå : ¿ëµµº° ÃßÁ¤ ¹× µ¿Ç⠺м®

  • ½ÃÀå Á¡À¯À² : ¿ëµµº°(2023³â, 2030³â)
  • ºÎ¹® ´ë½Ãº¸µå
  • ¼¼°èÀÇ ¸¶ÀÌÅ©·Î¾î·¹ÀÌ ½ÃÀå Àü¸Á : ¿ëµµº°
  • ½ÃÀå ±Ô¸ð ¿¹Ãø ¹× µ¿Ç⠺м®(2018-2030³â)
    • ¿¬±¸ ¿ëµµ
    • â¾à
    • Áúº´ Áø´Ü
    • ±âŸ ¿ëµµ

Á¦7Àå ¸¶ÀÌÅ©·Î¾î·¹ÀÌ ½ÃÀå : ÃÖÁ¾ ¿ëµµº° ÃßÁ¤ ¹× µ¿Ç⠺м®

  • ½ÃÀå Á¡À¯À² : ÃÖÁ¾ ¿ëµµº°(2023³â, 2030³â)
  • ºÎ¹® ´ë½Ãº¸µå
  • ¼¼°èÀÇ ¸¶ÀÌÅ©·Î¾î·¹ÀÌ ½ÃÀå Àü¸Á : ÃÖÁ¾ ¿ëµµº°
  • ½ÃÀå ±Ô¸ð ¿¹Ãø ¹× µ¿Ç⠺м®(2018-2030³â)
    • ¿¬±¸ ¹× Çмú±â°ü
    • Á¦¾à ¹× ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷
    • Áø´Ü ½ÇÇè½Ç
    • ±âŸ

Á¦8Àå ¸¶ÀÌÅ©·Î¾î·¹ÀÌ ½ÃÀå : Áö¿ªº° ÃßÁ¤ ¹× µ¿Ç⠺м®

  • ½ÃÀå Á¡À¯À² ºÐ¼® : Áö¿ªº°(2023³â, 2030³â)
  • ½ÃÀå ´ë½Ãº¸µå : Áö¿ªº°
  • ¼¼°è ½ÃÀå ÇöȲ : Áö¿ªº°
  • ½ÃÀå ±Ô¸ð ¿¹Ãø ¹× µ¿Ç⠺м®(2018-2030³â)
  • ºÏ¹Ì
    • ºÏ¹Ì : SWOT ºÐ¼®
    • ¹Ì±¹
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
  • À¯·´
    • À¯·´ : SWOT ºÐ¼®
    • ¿µ±¹
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ³ë¸£¿þÀÌ
    • ½º¿þµ§
    • µ§¸¶Å©
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ¾Æ½Ã¾ÆÅÂÆò¾ç : SWOT ºÐ¼®
    • ÀϺ»
    • Áß±¹
    • Àεµ
    • È£ÁÖ
    • Çѱ¹
    • ű¹
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ¶óƾ¾Æ¸Þ¸®Ä« : SWOT ºÐ¼®
    • ºê¶óÁú
    • ¾Æ¸£ÇîÆ¼³ª
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : SWOT ºÐ¼®
    • ³²¾ÆÇÁ¸®Ä«
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
    • Äí¿þÀÌÆ®

Á¦9Àå °æÀï ±¸µµ

  • ÃÖ±Ù µ¿Çâ ¹× ¿µÇ⠺м® : ÁÖ¿ä ½ÃÀå ÁøÃâ ±â¾÷º°
  • ±â¾÷ ¹× °æÀïÀÇ ºÐ·ù
  • º¥´õ »óȲ
    • ÁÖ¿ä À¯Åë¾÷ü ¹× ä³Î ÆÄÆ®³Ê ¸ñ·Ï
    • ÁÖ¿ä °í°´
    • ÁÖ¿ä ±â¾÷ÀÇ ½ÃÀå Á¡À¯À² ºÐ¼®(2023³â)
    • Thermo Fisher Scientific Inc(Applied Biosystems)
    • Agilent Technologies, Inc
    • Illumina, Inc
    • PerkinElmer
    • Schott(Applied Microarrays)
    • Danaher Corporation
    • Arrayit Corporation
    • Bio-Rad Laboratories, Inc
    • Microarrays Inc
AJY 25.05.29

Microarray Market Growth & Trends:

The global microarray market size is expected to reach USD 8.46 billion by 2030, registering a CAGR of 5.48% from 2025 to 2030, according to a new report by Grand View Research, Inc. Market drivers propelling market growth include a global rise in cancer cases and a wide range of applications of microarrays in sequencing, genome mapping, personalized medicines, and others. A rise in global R&D investments is also key in propelling growth as this would lead to a rise in the use of microarrays for research purposes to advance and improve in healthcare.

Microarrays have a wide range of applications such as research applications, drug discovery, disease diagnosis, genomic and proteomic research, plant and food research, agricultural research, among other applications. According to a report published by the American Academy of Neurology, chromosomal microarray analysis can be used to diagnose intellectual disabilities and disomic features, this test has also been recommended as a first line diagnostic test. Recent advances in proteomics and genomics coupled with human genome sequencing have led to an increase in several screenable drug targets. According to a report published by PNAS (Proceedings of the National Academy of Sciences of the United States of America), a miniature 3D cell culture microarray has been developed for high throughput toxicological assays.

The introduction of various types of array platforms offered by leading companies is also another factor anticipated to boost market potential. For instance, R&D Systems, a biological products company offers proteome profiler antibody array, a protein microarray used to measure over 119 proteins in one sample. With the use of this product, laboratory technicians do not need any specialized equipment additionally eliminating the need for western blot experiments.

In recent years, large scale market players have collaborated with small and medium scale companies to expand their existing product portfolio and geographical presence. For instance, in 2018, Merck signed an agreement with HistoCyte Laboratories Ltd., to distribute cell microarrays in the U.S. and other geographies thereby, facilitating researchers with a cost-effective and easy option.

The Asia Pacific region is expected to witness lucrative growth during the forecast period owing to rising regulatory approvals received by leading companies for microarrays. For instance, in 2015, Agilent Technologies Inc. received the China FDA approval for its SureScan Dx microarray scanner. The Middle East & African region is also anticipated to showcase immense opportunities due to the launch of new products in the region to improve the diagnosis of diseases. For instance, in 2017, Thermo Fisher Scientific, Inc. launched Axiom Africa array, this array captures genome-wide variation in African populations as well as in Europe and Asian populations.

Microarray Market Report Highlights:

  • Consumables held the largest market share of 49.73% in 2024. Instruments are expected to grow at the fastest rate over the forecast period, driven by the increasing demand for automation, precision, and scalability in molecular diagnostics and research applications.
  • DNA microarrays accounted for the largest revenue share in 2024. Protein microarrays are expected to grow at the fastest rate over the forecast period, owing to their increasing use in drug discovery, immune profiling, and biomarker validation.
  • The research applications segment dominated the microarray market in 2024, supported by increasing investments in genomics, proteomics, and biomedical innovation. The disease diagnostics segment is anticipated to grow at the fastest rate over the forecast period.
  • Research and academic institutes accounted for the largest revenue share of the market in 2024. The diagnostic laboratories segment is expected to grow at the fastest CAGR during the forecast period.
  • North America microarray market dominated the global industry and accounted for a 48.27% share in 2024. The microarray market in Asia Pacific is anticipated to witness significant growth, driven by the increasing investment in research and development activities.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product and Services
    • 1.2.2. Type
    • 1.2.3. Application
    • 1.2.4. End Use
    • 1.2.5. Regional scope
    • 1.2.6. Estimates and forecasts timeline.
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product and Services Outlook
    • 2.2.2. Type Outlook
    • 2.2.3. Application Outlook
    • 2.2.4. End Use Outlook
    • 2.2.5. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Microarray Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Rising demand for personalized medicine and genomic research
      • 3.2.1.2. Technological advancements in microarray platforms
      • 3.2.1.3. Expanding applications in diagnostics and infectious disease testing
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High cost of microarray instruments and consumables
  • 3.3. Microarray Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis

Chapter 4. Microarray Market: Product and Services Estimates & Trend Analysis

  • 4.1. Product and Services Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global Microarray Market by Product and Services Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. Consumables
      • 4.4.1.1. Consumables market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Instruments
      • 4.4.2.1. Instruments market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3. Software and Services
      • 4.4.3.1. Software and services market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Microarray Market: Type Estimates & Trend Analysis

  • 5.1. Type Market Share, 2023 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global Microarray Market by Type Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.4.1. DNA Microarray
      • 5.4.1.1. DNA Microarray market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2. Protein Microarray
      • 5.4.2.1. Protein microarray market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.3. Others
      • 5.4.3.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Microarray Market: Application Estimates & Trend Analysis

  • 6.1. Application Market Share, 2023 & 2030
  • 6.2. Segment Dashboard
  • 6.3. Global Microarray Market by Application Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 6.4.1. Research applications
      • 6.4.1.1. Research application market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2. Drug discovery
      • 6.4.2.1. Drug discovery market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3. Disease diagnostics
      • 6.4.3.1. Disease diagnostics market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.4. Others applications
      • 6.4.4.1. Others application market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Microarray Market: End use Estimates & Trend Analysis

  • 7.1. End use Market Share, 2023 & 2030
  • 7.2. Segment Dashboard
  • 7.3. Global Microarray Market by End use Outlook
  • 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 7.4.1. Research and Academic Institutes
      • 7.4.1.1. Research and Academic Institutes market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.2. Pharmaceutical and Biotechnology Companies
      • 7.4.2.1. Pharmaceutical and Biotechnology Companies market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.3. Diagnostic Laboratories
      • 7.4.3.1. Diagnostic Laboratories market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.4. Others
      • 7.4.4.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Microarray Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2023 & 2030
  • 8.2. Regional Market Dashboard
  • 8.3. Global Regional Market Snapshot
  • 8.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 8.5. North America
    • 8.5.1. North America: SWOT Analysis
    • 8.5.2. U.S.
      • 8.5.2.1. Key country dynamics
      • 8.5.2.2. Regulatory framework
      • 8.5.2.3. Competitive scenario
      • 8.5.2.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.3. Canada
      • 8.5.3.1. Key country dynamics
      • 8.5.3.2. Regulatory framework
      • 8.5.3.3. Competitive scenario
      • 8.5.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.4. Mexico
      • 8.5.4.1. Key country dynamics
      • 8.5.4.2. Regulatory framework
      • 8.5.4.3. Competitive scenario
      • 8.5.4.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6. Europe
    • 8.6.1. Europe: SWOT Analysis
    • 8.6.2. UK
      • 8.6.2.1. Key country dynamics
      • 8.6.2.2. Regulatory framework
      • 8.6.2.3. Competitive scenario
      • 8.6.2.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.3. Germany
      • 8.6.3.1. Key country dynamics
      • 8.6.3.2. Regulatory framework
      • 8.6.3.3. Competitive scenario
      • 8.6.3.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.4. France
      • 8.6.4.1. Key country dynamics
      • 8.6.4.2. Regulatory framework
      • 8.6.4.3. Competitive scenario
      • 8.6.4.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.5. Italy
      • 8.6.5.1. Key country dynamics
      • 8.6.5.2. Regulatory framework
      • 8.6.5.3. Competitive scenario
      • 8.6.5.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.6. Spain
      • 8.6.6.1. Key country dynamics
      • 8.6.6.2. Regulatory framework
      • 8.6.6.3. Competitive scenario
      • 8.6.6.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.7. Norway
      • 8.6.7.1. Key country dynamics
      • 8.6.7.2. Regulatory framework
      • 8.6.7.3. Competitive scenario
      • 8.6.7.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.8. Sweden
      • 8.6.8.1. Key country dynamics
      • 8.6.8.2. Regulatory framework
      • 8.6.8.3. Competitive scenario
      • 8.6.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.9. Denmark
      • 8.6.9.1. Key country dynamics
      • 8.6.9.2. Regulatory framework
      • 8.6.9.3. Competitive scenario
      • 8.6.9.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7. Asia Pacific
    • 8.7.1. Asia Pacific: SWOT Analysis
    • 8.7.2. Japan
      • 8.7.2.1. Key country dynamics
      • 8.7.2.2. Regulatory framework
      • 8.7.2.3. Competitive scenario
      • 8.7.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.3. China
      • 8.7.3.1. Key country dynamics
      • 8.7.3.2. Regulatory framework
      • 8.7.3.3. Competitive scenario
      • 8.7.3.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.4. India
      • 8.7.4.1. Key country dynamics
      • 8.7.4.2. Regulatory framework
      • 8.7.4.3. Competitive scenario
      • 8.7.4.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.5. Australia
      • 8.7.5.1. Key country dynamics
      • 8.7.5.2. Regulatory framework
      • 8.7.5.3. Competitive scenario
      • 8.7.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.6. South Korea
      • 8.7.6.1. Key country dynamics
      • 8.7.6.2. Regulatory framework
      • 8.7.6.3. Competitive scenario
      • 8.7.6.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.7. Thailand
      • 8.7.7.1. Key country dynamics
      • 8.7.7.2. Regulatory framework
      • 8.7.7.3. Competitive scenario
      • 8.7.7.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.8. Latin America
    • 8.8.1. Latin America: SWOT Analysis
    • 8.8.2. Brazil
      • 8.8.2.1. Key country dynamics
      • 8.8.2.2. Regulatory framework
      • 8.8.2.3. Competitive scenario
      • 8.8.2.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.8.3. Argentina
      • 8.8.3.1. Key country dynamics
      • 8.8.3.2. Regulatory framework
      • 8.8.3.3. Competitive scenario
      • 8.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.9. MEA
    • 8.9.1. MEA: SWOT Analysis
    • 8.9.2. South Africa
      • 8.9.2.1. Key country dynamics
      • 8.9.2.2. Regulatory framework
      • 8.9.2.3. Competitive scenario
      • 8.9.2.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.9.3. Saudi Arabia
      • 8.9.3.1. Key country dynamics
      • 8.9.3.2. Regulatory framework
      • 8.9.3.3. Competitive scenario
      • 8.9.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.9.4. UAE
      • 8.9.4.1. Key country dynamics
      • 8.9.4.2. Regulatory framework
      • 8.9.4.3. Competitive scenario
      • 8.9.4.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.9.5. Kuwait
      • 8.9.5.1. Key country dynamics
      • 8.9.5.2. Regulatory framework
      • 8.9.5.3. Competitive scenario
      • 8.9.5.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 9.2. Company/Competition Categorization
  • 9.3. Vendor Landscape
    • 9.3.1. List of key distributors and channel partners
    • 9.3.2. Key customers
    • 9.3.3. Key company market share analysis, 2023
    • 9.3.4. Thermo Fisher Scientific Inc (Applied Biosystems)
      • 9.3.4.1. Company overview
      • 9.3.4.2. Financial performance
      • 9.3.4.3. Services benchmarking
      • 9.3.4.4. Strategic initiatives
    • 9.3.5. Agilent Technologies, Inc
      • 9.3.5.1. Company overview
      • 9.3.5.2. Financial performance
      • 9.3.5.3. Services benchmarking
      • 9.3.5.4. Strategic initiatives
    • 9.3.6. Illumina, Inc
      • 9.3.6.1. Company overview
      • 9.3.6.2. Financial performance
      • 9.3.6.3. Services benchmarking
      • 9.3.6.4. Strategic initiatives
    • 9.3.7. PerkinElmer
      • 9.3.7.1. Company overview
      • 9.3.7.2. Financial performance
      • 9.3.7.3. Services benchmarking
      • 9.3.7.4. Strategic initiatives
    • 9.3.8. Schott (Applied Microarrays)
      • 9.3.8.1. Company overview
      • 9.3.8.2. Financial performance
      • 9.3.8.3. Services benchmarking
      • 9.3.8.4. Strategic initiatives
    • 9.3.9. Danaher Corporation
      • 9.3.9.1. Company overview
      • 9.3.9.2. Financial performance
      • 9.3.9.3. Services benchmarking
      • 9.3.9.4. Strategic initiatives
    • 9.3.10. Arrayit Corporation
      • 9.3.10.1. Company overview
      • 9.3.10.2. Financial performance
      • 9.3.10.3. Services benchmarking
      • 9.3.10.4. Strategic initiatives
    • 9.3.11. Bio-Rad Laboratories, Inc
      • 9.3.11.1. Company overview
      • 9.3.11.2. Financial performance
      • 9.3.11.3. Services benchmarking
      • 9.3.11.4. Strategic initiatives
    • 9.3.12. Microarrays Inc
      • 9.3.12.1. Company overview
      • 9.3.12.2. Financial performance
      • 9.3.12.3. Services benchmarking
      • 9.3.12.4. Strategic initiatives
»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦